Pierre Labbé | CFO |
Frederic Ors | CEO |
Neil Berinstein | Hematologist & Affiliate Scientist, Sunnybrook Institute |
Joanne Schindler | CMO |
Jim Birchenough | Wells Fargo Securities |
Tom Shrader | BTIG |
Ted Tenthoff | Piper Sandler |
David Novak | Raymond James |
Eduardo Garcia | National Bank Financial |
Good morning, ladies and gentlemen, and welcome to the IMV's Presentation of Data on Relapsed Refractory DLBCL Treated with DPX-Survivac, Low Dose Cyclophosphamide and Pembrolizumab, which will be combined with the presentation of IMV third-quarter results and highlights. At this time, all lines are in a listen-only mode. After each presentation, there will be a question and answer session and instructions will be provided at that time in order to queue up for questions. [Operator Instructions] I would now like to turn the meeting over to Mr. Pierre Labbé, Chief Financial Officer of IMV.